Jitendrakumar Gupta, MD
Pulmonary Disease · Sioux City, IANPI 1285710764
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $840 and has fallen 95.0% since, to $42 in 2025.
Across 132 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$407
- Boehringer Ingelheim$343
- Grifols USA, LLC$243
- AstraZeneca$206
- Mylan Specialty L.p.$173
- Inspire Medical Systems, Inc.$133
- plus $627 from 14 others
What the payments were for
- Food & beverage$2,04396%
- Education$884%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 31 | $407 |
| Boehringer Ingelheim | 18 | $343 |
| Grifols USA, LLC | 19 | $243 |
| AstraZeneca | 14 | $206 |
| Mylan Specialty L.p. | 10 | $173 |
| Inspire Medical Systems, Inc. | 1 | $133 |
| United Therapeutics Corporation | 8 | $114 |
| Insmed, Inc. | 6 | $103 |
| Sanofi | 3 | $59 |
| Sunovion Pharmaceuticals Inc. | 5 | $52 |
| Merck | 3 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Philips North America LLC | 3 | $44 |
| Actelion Pharmaceuticals US, Inc. | 2 | $41 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Itamar Medical Inc | 1 | $25 |
| Advanced Respiratory, Inc | 1 | $22 |
| Johnson & Johnson | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,131 in reported general payments places this provider in the 55th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 81 | $1,028,549 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 992 | $695,930 |
| NucalaMepolizumab | 143 | $522,570 |
| Breo ElliptaFluticasone/Vilanterol | 607 | $266,721 |
| Fasenra PenBenralizumab | 42 | $239,461 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 387 | $186,448 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $174,735 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 224 | $152,475 |
| Spiriva RespimatTiotropium Bromide | 227 | $150,300 |
| Dupixent SyringeDupilumab | 24 | $89,163 |
| Incruse ElliptaUmeclidinium Bromide | 167 | $63,164 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 114 | $61,000 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 242 | $43,651 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 293 | $42,622 |
| DuleraMometasone/Formoterol | 121 | $42,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $407 | $1,763,8802,397 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $343 | $1,239,849422 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $206 | $227,113449 claims |
| MerckDulera, Asmanex | $45 | $45,230138 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $41 | $34,47613 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $12 | $2,96111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Sioux City
- Sandeep GuptaSioux City$9K
- Bryan KrajicekCouncil Bluffs$470K
- Sumit MukherjeeCouncil Bluffs$264K
- John SouthardCouncil Bluffs$184K
- Dustin McCannWest Des Moines$67K
- Alejandro ComellasIowa City$54K
- Matthew TrumpWest Des Moines$41K
- Brian WittDavenport$19K
- Shrey VelaniDes Moines$18K
- James MallenWest Des Moines$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.